Danimer Scientific — Q2 2023 Earnings Presentation
12 slides from Danimer Scientific's earnings presentation, Aug 8, 2023
Slide 1: Second Quarter 2023 Earnings Presentation
Second Quarter 2023 Earnings Presentation August 8, 2023
Slide 2: Disclaimer and Forward-Looking Statements
This presentation (“Presentation”) is for informational purposes only. This Presentation shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation or sale w
Slide 3: Fast Facts
FAST FACTS Founded in 2004 (went public in 2020) 480 patents & pending patent applications 15 partnerships with major brands and distributors 255 Teammates 2018 and 2020 recipient of PLASTICS Innovation in Bioplastics Award Locations in Georgia, Kentucky and New York Manufacturer of PHA Biopolymers
Slide 4: Proprietary PHA-Based Resins with Disruptive Performance
Certified biodegradable for home compost, natural soil and marine environments Highly-engineered to run on standard manufacturing equipment Indistinguishable from petroleum-based plastic to consumers at end-use Proprietary PHA-Based Resins with Disruptive Performance 1 Switch to PHA-based resin requ
Slide 5: Recent Highlights
Received acceptance of Part 2 application to Department of Energy Loan Guarantee Program; Invited to now take part in due diligence and term sheet negotiation for potential Department of Treasury Federal Financing for construction of Bainbridge, GA greenfield facility Customer launch of Nodax®-based
Slide 6: Kentucky Manufacturing – Process & Capability
Kentucky Manufacturing – Process & Capability ¹ Intended to illustrate maximum potential at full utilization of design capacity; assumes pricing of $3 per lb. Facility Targets: ~32.5 M LBS of Neat PHA ~65 M LBS Formulated PHA-Based Resin ~$190 M Revenue¹ 6 Continuous innovation effort reveals potent
Slide 7: Q2 2023 Financial Summary
Q2 2023 Financial Summary 2Q23 sales increase both sequentially and versus last year with strength in sales of PHA-based resins (up 69% sequentially and up 10% versus prior year) offset by lower funded R&D revenue as customers move to commercialization as well as a modest reduction in sales of PLA-b
Slide 8: Guidance Summary
1Q23 and 2Q23 results have been in-line with expectations Believe a bias toward lower end of Adj. EBITDA guidance range is prudent due to later than originally expected timing of large new program awards and increased disruption from Ukraine-Russia conflict on PLA product sales Remain confident in n
Slide 9: tess, ~ e
AN y . tess, ~ e Zé danimer \ oe soienutic. ‘y __ ABiotechnology Company
Slide 10: EBITDA Reconciliation
danimer scientific EBITDA Reconciliation A Biotechnology Company $ Thousands Net income (loss) ($39,241) ($30,445) Stock-based compensation 13,666 14,546 Interest, net 9,162 652 Depreciation and amortization 7,173 4,328 Remeasurement of private warrants (1,083) (2,012) Loss on extinguishment of debt
Slide 11: Adjusted Gross Profit Reconciliation
Adjusted Gross Profit Reconciliation 11
Slide 12: Thank You
a danimer ~ scientific THANK YOU